Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Beijer Byggmaterial in connection with the acquisition of Kakeldax
Mandate

Vinge advises Beijer Byggmaterial in connection with the acquisition of Kakeldax

September 07, 2021 Employment and Benefits M&A Real Estate and Construction Corporate Commercial Intellectual Property

Vinge has advised Beijer Byggmaterial AB in connection with the acquisition of the Kakeldax group. The Kakeldax group consists of three strong brands – Stigs Kakel, Kakeldax and Kakelcentralen.

The group has more than 30 years of industry experience with 11 own stores, web shops and distributors across the country. The head office and central storage facility are located in Gothenburg.

Vinge’s team consisted of, among others, Jonas Bergström, Joacim Rydergård, Vilhelm Rondahl, Ellinor Wargenbrant and Beatrice Randow (M&A), Hedvig Ekdahl (Corporate Commercial), Frida Ställborn (Real Property/Lease Agreements), Lina Österberg (Environment), Karl-Hugo Engdahl (GDPR), Ebba Svenburg and Elin Broman (Employment Law), Felizia Wiker (IP) and Nathalie Hughes (VDR).

 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026